A new analysis pooled data from 697 patients with multiple myeloma. Researchers compared D-dimer levels between those considered high-risk and those in a reference group. High-risk was defined by advanced disease stage, a history of blood clots, or a higher chance of dying.
The results showed that D-dimer levels were significantly higher in the high-risk group. The difference was large, with a standardized mean difference of 1.60. This means the gap between groups was substantial and unlikely due to chance.
D-dimer is a protein fragment released when blood clots break down. In multiple myeloma, abnormal proteins and treatments can raise clot risk. This study suggests D-dimer could be a useful marker for identifying patients who might benefit from closer monitoring or preventive blood thinners.
However, the analysis has limits. The authors note that prospective studies are needed to confirm these findings. Also, the study did not report on side effects or follow-up time. More research is needed before D-dimer testing becomes a standard part of care for multiple myeloma.
Still, the findings point to a simple blood test that could one day help doctors personalize treatment and reduce complications for people with this cancer.
Common questions
What is D-dimer and why does it matter in multiple myeloma?
D-dimer is a protein fragment made when blood clots break down. In this analysis of 697 myeloma patients, those in a high-risk group had significantly higher D-dimer levels than the reference group. That suggests D-dimer might someday help doctors identify who needs closer monitoring, but it is not yet a proven tool.
Does this mean D-dimer testing should change my myeloma treatment?
Not based on this analysis alone. The researchers say prospective validation studies are needed before D-dimer is used to guide risk stratification or clot-prevention plans. If you have myeloma and want to know whether D-dimer testing is right for you, ask your doctor.
How many people were in this study and who were they?
The analysis included 697 patients with multiple myeloma. Of those, 171 were in a high-risk group based on advanced disease stage, a history of venous thromboembolism, or a predictor of mortality. The other 526 patients made up the reference group.
Were there any side effects or safety concerns reported?
No adverse events, serious adverse events, or discontinuations were reported in this meta-analysis. The study looked at D-dimer levels in blood samples, not at a treatment or drug, so safety concerns about a therapy do not apply here.
